Epidemiology and burden of oral complications (OCs) following breast cancer treatment: A Systematic Literature Review-Risk factors for development of OCs
Guardat en:
| Autors: | , |
|---|---|
| Format: | artículo original |
| Data de publicació: | 2023 |
| Descripció: | Breast cancer (BC), the most prevalent malignancy among women, has good survival rates given the numerous treatments available according to disease and patient characteristics. However, all treatments are associated with several adverse effects (AE) including oral-health complications (OC). Negative oral health is commonly reported during and after BC treatment, yet OCs are often overlooked or receive delayed interventions that are mostly performed empirically. This systematic literature review (SLR) aims to generate evidence that can provide the basis for the development of oral health management protocols for this particular population. Methods: Systematic searches on the epidemiology and burden of OCs after any BC treatment were conducted in seven electronic databases including Embase and Medline until July 2023. The authors screened all articles independently against pre-determined criteria and assessed for quality following the Cochrane Collaboration and PRISMA guidelines. Protocol registered in PROSPERO (CRD42021272130). Here, we describe the data on the risk factors for development of OCs. Results: Out of the 6,488 unique records identied, 1,118 full-text articles were assessed for eligibility and 742 articles met the inclusion criteria. The number of publications has increased overtime from 1979 to 2023, predominantly with interventional studies assessing the efcacy of treatment for BC (non-randomized interventions or randomized controlled trials, n = 549). The incidence of mucositis or stomatitis was reported in 85% of the all the included studies (n = 650). Most of the 48 studies assessing risk factors for development of OCs, evaluated the association of type of BC treatment. Overall, all chemotherapy regimens are reported to increase the risk of developing stomatitis and mucositis, but capecitabine users were signicantly most likely to develop mild stomatitis and taxane-based therapies increased the risk of severe mucositis. The targeted therapy everolimus signicantly increased the risk of developing severe stomatitis. Data in demographic risk factors to develop OCs is limited but there was an association reported between OCs and older age. Conclusions: This SLR shows that the incidence and impact of oral complications following BC treatment, other than mucositis and stomatitis, are underreported by the medical literature reecting an unmet need for patients and an opportunity for research. The epidemiology, quality of life and economic burden of OCs, treatment efcacy and recommendations will be reported in future publications. |
| Pais: | Kérwá |
| Institution: | Universidad de Costa Rica |
| Repositorio: | Kérwá |
| Idioma: | Inglés |
| OAI Identifier: | oai:kerwa.ucr.ac.cr:10669/104688 |
| Accés en línia: | https://www.johamsc.com/?v=vm&manid=3051 https://hdl.handle.net/10669/104688 |
| Paraula clau: | Oral complications Breast cancer treatment Antineoplastic agent effects Adverse events incidence Preventive medicine Applied research Documentary analysis Therapy Medical research |